Agios to Present at March Investor Conferences
Agios Pharmaceuticals (NASDAQ:AGIO) announced its participation in two upcoming virtual investor conferences in March 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agios Pharmaceuticals (NASDAQ:AGIO) announced its participation in two upcoming virtual investor conferences in March 2021. The first is the Cowen 41st Annual Virtual Healthcare Conference on March 1, 2021, at 11:40 a.m. ET, followed by the Oppenheimer 31st Annual Virtual Healthcare Conference on March 17, 2021, at 9:20 a.m. ET. Live webcasts of the presentations will be available on Agios's website, with replays archived for at least two weeks post-event. The company focuses on developing treatments for cancer and genetic diseases through cellular metabolism research.
Details
News Market Reaction – AGIO
The recorded move for AGIO in the trading session of this news was +0.61%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company is scheduled to present at the following March investor conferences:
- Cowen 41st Annual Virtual Healthcare Conference on Monday, March 1, 2021 at 11:40 a.m. ET; and
- Oppenheimer 31st Annual Virtual Healthcare Conference on Wednesday, March 17, 2021 at 9:20 a.m. ET.
Live webcasts of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. Replays of the webcasts will be archived on the Agios website for at least two weeks following each presentation.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and genetically defined diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company's website at www.agios.com.
Contacts
Investors & Media:
Holly Manning, 617-844-6630
Director, Investor Relations
Holly.Manning@agios.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.